B lymphocytes as therapeutic targets in systemic lupus erythematosus

Bibliography

• ZOUALI M: Taming lupus. Sci. Am. (2005) 292:70-77.
   Google Scholar
• ABU-SHAKRA M, SHOENFELD Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus (2001) 10(3):152-153.
   PubMed Web of Science ®Google Scholar
• CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. (2000) 343(16):1156-1162.
   PubMed Web of Science ®Google Scholar
• GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. (2005) 353(21):2219-2228.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. (2001) 2(9):764-766.
   PubMed Web of Science ®Google Scholar
• VIAU M, ZOUALI M: B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. (2005) 114(1):17-26.
   PubMed Web of Science ®Google Scholar
• LIM PL, ZOUALI M: Pathogenic autoantibodies: emerging insights into tissue injury. Immunol. Lett. (2006) 103(1):17-26.
   PubMedGoogle Scholar
• SUZUKI N, MIHARA S, SAKANE T: Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus. FASEB J. (1997) 11(12):1033-1038.
   PubMed Web of Science ®Google Scholar
• KOREN E, KOSCEC M, WOLFSON-REICHLIN M et al.: Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells. J. Immunol. (1995) 154(9):4857-4864.
   PubMed Web of Science ®Google Scholar
• KOSCEC M, KOREN E, WOLFSON-REICHLIN M et al.: Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J. Immunol. (1997) 159(4):2033-2041.
   PubMedGoogle Scholar
• TARZI RM, DAVIES KA, CLAASSENS JW et al.: Both Fcγ receptor I and Fcγ receptor III mediate disease in accelerated nephrotoxic nephritis. Am. J. Pathol. (2003) 162(5):1677-1683.
   PubMedGoogle Scholar
• LANZAVECCHIA A: Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Ann. Rev. Immunol. (1990) 8:773-793.
   PubMed Web of Science ®Google Scholar
• TIGHE H, CHEN PP, TUCKER R et al.: Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. J. Exp. Med. (1993) 177(1):109-118.
   PubMed Web of Science ®Google Scholar
• ROOSNEK E, LANZAVECCHIA A: Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J. Exp. Med. (1991) 173(2):487-489.
   PubMed Web of Science ®Google Scholar
• RIFKIN IR, LEADBETTER EA, BEAUDETTE BC et al.: Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J. Immunol. (2000) 165(3):1626-1633.
   PubMed Web of Science ®Google Scholar
• LEADBETTER EA, RIFKIN IR, HOHLBAUM AM et al.: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 416(6881):603-607.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, WEYAND CM: T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. (2001) 167(8):4710-4718.
   PubMed Web of Science ®Google Scholar
• ZOUALI M, SARMAY G: B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. (2004) 50(9):2730-2741.
   PubMed Web of Science ®Google Scholar
• KEYSTONE E: B cell targeted therapies. Arthritis Res. Ther. (2005) 7(Suppl. 3):S13-S18.
   PubMedGoogle Scholar
• LUZINA IG, ATAMAS SP, STORRER CE et al.: Spontaneous formation of germinal centers in autoimmune mice. J. Leukoc. Biol. (2001) 70(4):578-584.
   PubMed Web of Science ®Google Scholar
• ARCE E, JACKSON DG, GILL MA et al.: Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. (2001) 167(4):2361-2369.
   PubMed Web of Science ®Google Scholar
• DATTA SK, KALLED SL: CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. (1997) 40(10):1735-1745.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48(3):719-727.
   PubMed Web of Science ®Google Scholar
• GRAMMER AC, SLOTA R, FISCHER R et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. (2003) 112(10):1506-1520.
   PubMed Web of Science ®Google Scholar
• KALUNIAN KC, DAVIS JC Jr, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(12):3251-3258.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, JR., TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. (2001) 28(1):95-101.
   PubMed Web of Science ®Google Scholar
• FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science (1994) 265(5176):1225-1227.
   PubMed Web of Science ®Google Scholar
• DAIKH DI, WOFSY D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. (2001) 166(5):2913-2916.
   PubMed Web of Science ®Google Scholar
• KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. (2003) 349(20):1907-1915.
   PubMed Web of Science ®Google Scholar
• MAURY CP, TEPPO AM: Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. (1989) 32(2):146-150.
   PubMedGoogle Scholar
• STUDNICKA-BENKE A, STEINER G, PETERA P, SMOLEN JS: Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol. (1996) 35(11):1067-1074.
   PubMedGoogle Scholar
• GABAY C, CAKIR N, MORAL F et al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. (1997) 24(2):303-308.
   PubMed Web of Science ®Google Scholar
• MALIDE D, RUSSO P, BENDAYAN M: Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum. Pathol. (1995) 26(5):558-564.
   PubMed Web of Science ®Google Scholar
• HERRERA-ESPARZA R, BARBOSA-CISNEROS O, VILLALOBOS-HURTADO R, AVALOS-DIAZ E: Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus (1998) 7(3):154-158.
   PubMed Web of Science ®Google Scholar
• UEDA Y, YANG K, FOSTER SJ, KONDO M, KELSOE G: Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J. Exp. Med. (2004) 199(1):47-58.
   PubMedGoogle Scholar
• ARINGER M, GRANINGER WB, STEINER G, SMOLEN JS: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. (2004) 50(10):3161-3169.
   PubMed Web of Science ®Google Scholar
• DEBANDT M, VITTECOQ O, DESCAMPS V, LE LOET X, MEYER O: Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol. (2003) 22(1):56-61.
   PubMed Web of Science ®Google Scholar
• TYRRELL-PRICE J, LYDYARD PM, ISENBERG DA: The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin. Exp. Immunol. (2001) 124(1):118-125.
   PubMedGoogle Scholar
• PARK YB, LEE SK, KIM DS et al.: Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin. Exp. Rheumatol. (1998) 16(3):283-288.
   PubMed Web of Science ®Google Scholar
• LLORENTE L, ZOU W, LEVY Y et al.: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. (1995) 181(3):839-844.
   PubMed Web of Science ®Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, GARCIA-PADILLA C et al.: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. (2000) 43(8):1790-1800.
   PubMed Web of Science ®Google Scholar
• MACKAY F, SCHNEIDER P, RENNERT P, BROWNING J: BAFF and APRIL: a tutorial on B cell survival. Ann. Rev. Immunol. (2003) 21:231-264.
   PubMed Web of Science ®Google Scholar
• GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 404(6781):995-999.
   PubMed Web of Science ®Google Scholar
• THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 293(5537):2108-2111.
   PubMed Web of Science ®Google Scholar
• AVERY DT, KALLED SL, ELLYARD JI et al.: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. (2003) 112(2):286-297.
   PubMed Web of Science ®Google Scholar
• AMANNA IJ, CLISE-DWYER K, NASHOLD FE, HOAG KA, HAYES CE: Cutting edge: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis. J. Immunol. (2001) 167(11):6069-6072.
   PubMed Web of Science ®Google Scholar
• GORELIK L, CUTLER AH, THILL G et al.: Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J. Immunol. (2004) 172(2):762-766.
   PubMed Web of Science ®Google Scholar
• HASE H, KANNO Y, KOJIMA M et al.: BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood (2004) 103(6):2257-2265.
   PubMed Web of Science ®Google Scholar
• ZOUALI M: B cell diversity and longevity in systemic autoimmunity. Mol. Immunol. (2002) 38(12-13):895-901.
   PubMed Web of Science ®Google Scholar
• JACOB CO, PRICOP L, PUTTERMAN C et al.: Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. (2006) 177(4):2671-2680.
   PubMed Web of Science ®Google Scholar
• LESLEY R, XU Y, KALLED SL et al.: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 20(4):441-453.
   PubMed Web of Science ®Google Scholar
• KAYAGAKI N, YAN M, SESHASAYEE D et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 17(4):515-524.
   PubMed Web of Science ®Google Scholar
• NG LG, SUTHERLAND AP, NEWTON R et al.: B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. (2004) 173(2):807-817.
   PubMed Web of Science ®Google Scholar
• HUARD B, ARLETTAZ L, AMBROSE C et al.: BAFF production by antigen-presenting cells provides T cell co-stimulation. Int. Immunol. (2004) 16(3):467-475.
   PubMedGoogle Scholar
• BOULE MW, BROUGHTON C, MACKAY F et al.: Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. (2004) 199(12):1631-1640.
   PubMed Web of Science ®Google Scholar
• KHARE SD, SAROSI I, XIA XZ et al.: Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA (2000) 97(7):3370-3375.
   PubMed Web of Science ®Google Scholar
• GROOM J, KALLED SL, CUTLER AH et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J. Clin. Invest. (2002) 109(1):59-68.
   PubMed Web of Science ®Google Scholar
• STOHL W, XU D, KIM KS et al.: BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. (2005) 52(7):2080-2091.
   PubMed Web of Science ®Google Scholar
• PERS JO, DARIDON C, DEVAUCHELLE V et al.: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. NY Acad. Sci. (2005) 1050:34-39.
   PubMed Web of Science ®Google Scholar
• CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. (2001) 44(6):1313-1319.
   PubMed Web of Science ®Google Scholar
• CARTER RH, ZHAO H, LIU X et al.: Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum. (2005) 52(12):3943-3954.
   PubMed Web of Science ®Google Scholar
• RAMANUJAM M, WANG X, HUANG W et al.: Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. (2006) 116(3):724-734.
   PubMed Web of Science ®Google Scholar
• BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 48(11):3253-3265.
   PubMed Web of Science ®Google Scholar
• DING C, JONES G: Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs (2006) 7(5):464-472.
   PubMed Web of Science ®Google Scholar
• STOHL W: SLE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther. (2003) 5(3):136-138.
   PubMed Web of Science ®Google Scholar
• GROSS JA, DILLON SR, MUDRI S et al.: TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 15(2):289-302.
   PubMed Web of Science ®Google Scholar
• PELLETIER M, THOMPSON JS, QIAN F et al.: Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J. Biol. Chem. (2003) 278(35):33127-33133.
   PubMed Web of Science ®Google Scholar
• LI H, AYER LM, LYTTON J, DEANS JP: Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. (2003) 278(43):42427-42434.
   PubMed Web of Science ®Google Scholar
• BINDER M, OTTO F, MERTELSMANN R, VEELKEN H, TREPEL M: The epitope recognized by rituximab. Blood (2006) 108(6):1975-1978.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, LEANDRO MJ, CAMBRIDGE G: B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2004) 30(2):393-403, viii.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350(25):2572-2581.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673-2677.
   PubMed Web of Science ®Google Scholar
• WEIDE R, HEYMANNS J, PANDORF A, KOPPLER H: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 12(10):779-782.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK J, SANZ I: Treatment of SLE with anti-CD20 monoclonal antibody. Curr. Dir. Autoimmun. (2005) 8:193-205.
   PubMedGoogle Scholar
• LEVINE TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. (2005) 52(2):601-607.
   PubMed Web of Science ®Google Scholar
• COOPER HL, HEALY E, THEAKER JM, FRIEDMANN PS: Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin. Exp. Dermatol. (2003) 28(4):366-368.
   PubMed Web of Science ®Google Scholar
• MORRISON LH: Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J. Am. Acad. Dermatol. (2004) 51(5):817-819.
   PubMed Web of Science ®Google Scholar
• ZECCA M, NOBILI B, RAMENGHI U et al.: Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood (2003) 101(10):3857-3861.
   PubMed Web of Science ®Google Scholar
• WAKIM M, SHAH A, ARNDT PA et al.: Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency. Am. J. Hematol. (2004) 76(2):152-155.
   PubMed Web of Science ®Google Scholar
• STASI R, PAGANO A, STIPA E, AMADORI S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood (2001) 98(4):952-957.
   PubMed Web of Science ®Google Scholar
• GIAGOUNIDIS AA, ANHUF J, SCHNEIDER P et al.: Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur. J. Haematol. (2002) 69(2):95-100.
   PubMed Web of Science ®Google Scholar
• COOPER N, STASI R, CUNNINGHAM-RUNDLES S et al.: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. (2004) 125(2):232-239.
   PubMed Web of Science ®Google Scholar
• STASI R, BRUNETTI M, STIPA E, AMADORI S: Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood (2004) 103(12):4424-4428.
   PubMed Web of Science ®Google Scholar
• SPECKS U, FERVENZA FC, MCDONALD TJ, HOGAN MC: Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. (2001) 44(12):2836-2840.
   PubMed Web of Science ®Google Scholar
• SANSONNO D, DE RE V, LAULETTA G et al.: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood (2003) 101(10):3818-3826.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 40(2):205-211.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, BARNARD J, CAPPIONE A et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. (2004) 50(11):3580-3590.
   PubMed Web of Science ®Google Scholar
• SFIKAKIS PP, BOLETIS JN, TSOKOS GC: Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. (2005) 17(5):550-557.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, CAMBRIDGE G, EDWARDS JC, EHRENSTEIN MR, ISENBERG DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 44(12):1542-1545.
   PubMed Web of Science ®Google Scholar
• NG KP, LEANDRO MJ, EDWARDS JC et al.: Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis. (2006) 65(7):942-945.
   PubMed Web of Science ®Google Scholar
• GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. (2005) 64(6):913-920.
   PubMed Web of Science ®Google Scholar
• SFIKAKIS PP, BOLETIS JN, LIONAKI S et al.: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. (2005) 52(2):501-513.
   PubMed Web of Science ®Google Scholar
• MARKS SD, PATEY S, BROGAN PA et al.: B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. (2005) 52(10):3168-3174.
   PubMed Web of Science ®Google Scholar
• WILLEMS M, HADDAD E, NIAUDET P et al.: Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr. (2006) 148(5):623-627.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res. Ther. (2003) 5(Suppl. 4):S12-S16.
   PubMed Web of Science ®Google Scholar
• SZODORAY P, ALEX P, DANDAPANI V et al.: Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand. J. Immunol. (2004) 60(1-2):209-218.
   PubMedGoogle Scholar
• DANIELS I, ABULAYHA AM, THOMSON BJ, HAYNES AP: Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis (2006) 11(6):1013-1023.
   PubMedGoogle Scholar
• JAZIREHI AR, VEGA MI, CHATTERJEE D, GOODGLICK L, BONAVIDA B: Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by rituximab. Cancer Res. (2004) 64(19):7117-7126.
   PubMed Web of Science ®Google Scholar
• JAZIREHI AR, HUERTA-YEPEZ S, CHENG G, BONAVIDA B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. (2005) 65(1):264-276.
   PubMed Web of Science ®Google Scholar
• CAMBRIDGE G, LEANDRO MJ, EDWARDS JC et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48(8):2146-2154.
   PubMed Web of Science ®Google Scholar
• CROW MK: Modification of accessory molecule signaling. Springer Semin. Immunopathol. (2006) 27(4):409-424.
   PubMedGoogle Scholar
• UCHIDA J, HAMAGUCHI Y, OLIVER JA et al.: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. (2004) 199(12):1659-1669.
   PubMed Web of Science ®Google Scholar
• ROBERTS WK, LIVINGSTON PO, AGUS DB et al.: Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood (2002) 99(10):3748-3755.
   PubMed Web of Science ®Google Scholar
• HUANG J, SHEU JJ, WU SC, CHANG TW: Down regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG Fc fragment. Immunol. Lett. (2002) 81(1):49-58.
   PubMedGoogle Scholar
• TEDDER TF, POE JC, HAAS KM: CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. (2005) 88:1-50.
   PubMed Web of Science ®Google Scholar
• O’KEEFE TL, WILLIAMS GT, DAVIES SL, NEUBERGER MS: Hyperresponsive B cells in CD22-deficient mice. Science (1996) 274(5288):798-801.
   PubMed Web of Science ®Google Scholar
• OTIPOBY KL, ANDERSSON KB, DRAVES KE et al.: CD22 regulates thymus-independent responses and the lifespan of B cells. Nature (1996) 384(6610):634-637.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, LINK BK: Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. (2002) 29(1 Suppl. 2):81-86.
   PubMed Web of Science ®Google Scholar
• DORNER T, KAUFMANN J, WEGENER WA et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. (2006) 8(3):R74.
   PubMed Web of Science ®Google Scholar
• TUSCANO JM, O’DONNELL RT, MIERS LA et al.: Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood (2003) 101(9):3641-3647.
   PubMedGoogle Scholar
• MACKAY F, WOODCOCK SA, LAWTON P et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. (1999) 190(11):1697-1710.
   PubMed Web of Science ®Google Scholar
• THIEN M, PHAN TG, GARDAM S et al.: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 20(6):785-798.
   PubMed Web of Science ®Google Scholar
• YAZAWA N, HAMAGUCHI Y, POE JC, TEDDER TF: Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc. Natl. Acad. Sci. USA (2005) 102(42):15178-15183.
   PubMed Web of Science ®Google Scholar
• JONES DS, BARSTAD PA, FEILD MJ et al.: Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J. Med. Chem. (1995) 38(12):2138-2144.
   PubMed Web of Science ®Google Scholar
• WALLACE DJ, TUMLIN JA: LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus (2004) 13(5):323-327.
   PubMed Web of Science ®Google Scholar